Portfolio

Our solution

Complex solution for Alzheimer´s disease therapy development from idea to real solution.

Three different drug substances by now (Agora 1, Agora 2, Agora 3).
Each of them different approach how to combat Alzheimer´s disease.
Different Alzheimer’s disease pathways as targets for our drug candidates to minimize the failure.

AGORA 1 Combination of two drugs, that already exist on the market alone.	AGORA 2 One substance that has in its structure two active substances already know.	AGORA 3 Brand new substance that has never been described before.

Phase	Primary goal	Dose	Patient monitor	Typical number of participants	Success rate
Preclinical	Testing of drug in non-human subjects, to gather information on efficacy, safety and pharmacokinetics	Unrestricted	Scientific researcher	Not applicable (in vitro and animal studies only)
Phase 1	Testing of drug on healthy volunteers for safety and pharmakokinetics	Starting at subtherapeutic dose, but with ascending to therpeutic levels	Clinical researcher	20–100 normal/ elderly healthy volunteers	Approx. 70%
Phase 2	Testing of drug on patients to assess safety / tolerability; first assesmaent of efficacy	Therapeutic dose	Clinical researcher	100–300 patients with specific diseases	Approx. 33%
Phase 3	Testing of drug on patients to assess efficacy and safety	Therapeutic dose	Clinical researcher and personal physician	300–3,000 patients with specific diseases	25–30%